TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes HbA1C \<= 12.0% within the past 12 months;~* BMI \<= 45.0 kg/m2~* Initiation, addition of, change to, or continuation of basal insulin therapy with insulin detemir as deemed necessary by Investigator~Exclusion Criteria:~* Anticipated change in concomitant medication known to interfere with glucose metabolism such as systemic steroids, non-selective beta-blockers or mono amine oxidase (MAO) inhibitors.~* Proliferative retinopathy or maculopathy that has required acute treatment within the last 6 months.~* Any glucose lowering medication that is not indicated in combination with insulin, such as GLP-1 Analogues~* Known hypoglycemia unawareness or recurrent major hypoglycemia, as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Adolescents With Depression Study (TADS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis DSM-IV of Major Depressive Disorder, pervasive and stable; Children's Depression Rating Scale-R total score at least 45; Ages 12-17 inclusive; Grade in school: 6-12; Full-Scale IQ at least 80; Medication-free before start of study; Outpatient; Parent (or family member) involvement~Exclusion Criteria:~* Bipolar disorder; Severe Conduct Disorder; Substance Use/Abuse/Dependence; Pervasive Developmental Disorders; Thought Disorder; Suicidality or homicidality; Concurrent treatment with psychotropic drug (stable stimulant for ADHD permitted) or psychotherapy outside study; Two previous failed SSRI trials or a failed trial of CBT for depression; Intolerance to fluoxetine; Non-English speaking patient; Pregnancy or breastfeeding; No phone in home; Lack of parent or family member)involvement.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* first pharmacy claim for Tofacitinib and then Etanercept or Adalimumab between Jan 2014 and Sep 2016 represents the index claim~* First, select patients receiving ≥1 Tofacitinib pharmacy claim (Jan 2014-Sep 2016) who did not have a Tofacitinib claim anytime prior to index~* Patients do have \>1 advanced therapy filled on index date~* Physician diagnosis of Rheumatoid Arthritis (in any position) during the 1-year pre-index period, or on the index date~* Age 18+ years at index~Exclusion Criteria:~-None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Truven Health MarketScan (Type: None): The Truven Health MarketScan Research Databases reflects the combined healthcare service use of individuals covered by Truven Health clients (including employers, health plans, and hospitals) nationwide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Cyclophosphamide for Treatment of Scleroderma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet established criteria for a diagnosis of diffuse cutaneous scleroderma and have evidence of moderately severe organ damage and clinical evidence of active disease.~* Patients with diffuse scleroderma who have evidence of active fibrosing alveolitis manifested by either a greater than 10% decline in the forced vital capacity or the diffusing capacity from the defined normal values or from baseline measurements.~* Patients with severe deforming localized scleroderma (generalized morphea, liner morphea, keloid or bullous scleroderma) that threatens their capacity to function normally in society.~Exclusion Criteria:~* Age less than 18 years and over 70 years~* Any risk of pregnancy~* Cardiac ejection fraction of \< 45%~* Serum creatinine \> 3.0~* Patients who are pre-terminal or moribund~* Bilirubin \> 2.0, transaminases \> 2x normal~* Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), (5/30/01) \< 50% predicted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IV Cyclophosphamide (50 mg/kg) (Type: EXPERIMENTAL): This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CHILDREN HAVE BLOOD PRESSURE LEVEL =\>95TH PERCENTILE FOR AGE,GENDER \& HEIGHT~* PARENTAL CONSENT MUST BE GRANTED~Exclusion Criteria:~* BLOOD PESSURE IS =\>25% HIGHER THAN 95TH PERCENTILE FOR AGE, GENDER \& HEIGHT~* SERIOUS, CLINICALLY SIGNIFICANT FINDINGS UPON EXAMINATION AND LABORATORY OR OTHER ASSESSMENTS~Other protocol-defined exclusion criteria will apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Menopausal Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females who are currently physically well and between 45 and 65 years of age~* Current DSM-IV diagnosis of depression disorder~* Able to give informed consent~* Menopausal as determined by standardized classification guidelines for female reproductive aging were proposed at the Stages of Reproductive (STRAW) -Aging Workshop and symptom profile on the STRAW~* First-onset or relapse depression during menopause~* Currently taking either an SSRI or SNRI, or no psychotropic medication at all~* Evidence of a normal mammogram in the preceding 12 months.~Exclusion Criteria:~* Patients with known abnormalities in the hypothalamic-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event, breast pathology, undiagnosed vaginal bleeding or abnormal Pap smear results in the previous 2 years.~* Patients with any significant unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; or the presence of illness causing immobilisation.~* Patients experiencing severe melancholia, neurovegetative symptoms or current suicidality necessitating acute hospitalisation or intensive psychiatric treatment.~* Patients with psychotic symptoms or past history of severe mental illness including schizophrenia.~* Use of any form of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including Tibolone or use of phytoestrogen supplements as powder or tablet~* Pregnancy / Lactation~* Smoking cigarettes or other nicotine products~* Illicit drug use~* More than 3 standard drinks per day

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tibolone (Type: ACTIVE_COMPARATOR): Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
- Placebo (Type: NO_INTERVENTION): Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to the Screening Visit~* Normal lid/lash anatomy, blinking function and closure as determined by the Investigator~* Literate, able to speak English, and able to complete questionnaires independently~Exclusion Criteria:~* Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the Investigator, may lead to risk of clinically significant increased bleeding~* Nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas~* Contact lens use within 7 days prior to the Screening Visit or anticipate the use of contact lenses at any time during the study~* Corneal transplant in either or both eyes~* Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic or active implanted electronic device in the head~* A woman who is pregnant, nursing an infant, or planning a pregnancy during the duration of the study~* Currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to the Screening Visit

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TrueTear (Type: EXPERIMENTAL): The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subjects between the ages of 18 and 75 years, inclusive~* Must have moderate-to-severe, active Rheumatoid Arthritis~* Must have had an inadequate response to Methotrexate~* Subjects may have received one approved TNF inhibiting biologic agent that was inadequately effective and/or not tolerated~Exclusion Criteria~* Subjects with any acute or chronic infections or infection history~* Have acute or active chronic dermatological disorders prior to study start~* Any major illness/condition(s) or evidence of an unstable clinical condition that in the judgment of the investigator would make the subject inappropriate for entry into this study~* Known immunodeficiency disorder or a first degree relative with hereditary immunodeficiency~* Any live (attenuated) vaccines or current routine household contact with anyone who has received live (attenuated) vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06651600 (Type: EXPERIMENTAL): Study Drug
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients must have a documented history of at least one of the following:~* Hypertension (defined as systolic blood pressure 140 mmHg or a diastolic blood pressure 90 mmHg (defined as the disapperance of all sound \[Korotkoff Phase V\] or receiving anti-hypertensive treatment. Blood pressure should be measured after sitting the patient quietly for 3 minutes).~* Retinopathy (defined as any of the following; non-proliferative retinopathy, pre-pre-proliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease or history of photocoagulation).~* Microalbuminuria (defined as either, Albumin creatinine ratio \> than = to 2.5 mg/mmol, or Albumin excretion rate on a timed collection \> than = to 20 mcg/min (\> than = to 30 mg/24hrs) on two successive occasions, or a positive micral or other strip test).~* Macroalbuminuria (defined as either; Albustix or other dipstick evidence of gross proteinuria, Albumin creatinine ratio \> than = to 25 mg/mmol; or Albumin excretion rate on a timed collection \> than = 200 mcg/min (\> than = 300 mg/24hrs) on two sucessive occasions).~* Current smoker~Exclusion Criteria:~* Type I Diabetes Mellitus~* Any major Coronary event prior to entry into the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe COPD~* At least one COPd exacerbation in previous year~Exclusion Criteria:~* Asthma, allergic rhinitis or other atopic disease~* Unstable concurrent disease:~* Evidence of heart failure

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BDP/FF (Type: EXPERIMENTAL): Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
- Formoterol fumarate (Type: ACTIVE_COMPARATOR): Formoterol fumarate 12 µg per metered dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of rheumatoid arthritis~* Meets Class I, II or III of the ACR 1991 Revised Criteria~* RA seropositivity~* Stable dose of methotrexate~* Inadequate response to TNF inhibitors~Exclusion Criteria:~* Any prior treatment with lymphocyte depleting therapies~* History of active TB infection~* Known or screen test positive for specific viruses or indicators of viral infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - PF-05280586 (Type: EXPERIMENTAL): None
- B - Rituximab EU (Type: ACTIVE_COMPARATOR): None
- C- Rituximab-US (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COPD (FEV1/FVC\<0.7)~* Age 40-75~* Pulmonary hypertension (Vmax TI\>=2.8m/sec)~Exclusion Criteria:~* Treatment with CYP3A4 inhibitors, nitrates, PDE-5 inhibitors~* Coronary disease~* Ischemic optical neuritis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Sildenafil 20mg
- 2 (Type: ACTIVE_COMPARATOR): Sildenafil 40mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with ADPKD with polycystic liver (\> 20 liver cysts)~* Renal function MDRD \>40 ml/hr~* Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements~Exclusion Criteria:~* Kidney transplantation~* Renal failure requiring hemodialysis~* Use of oral contraceptives or estrogen suppletion~* Women who are pregnant or breastfeeding~* History of cardiac/pulmonary disease; symptomatic gallstones, pancreatitis, etc~* Intervention (aspiration or surgical intervention) within three months from baseline~* Treatment with somatostatin analogues within three months from baseline~* Mental illness that interferes with the patient ability to comply with the protocol~* Drug or alcohol abuse within one year from baseline~* Abnormal liver function tests, as determined by blood test (except isolated elevated GGT and AP, which occurs frequently in PLD)~* Clinical diagnosis of pancreatitis~* Diagnosis of diabetes mellitus, as determined by blood test and medical history~* Use of drugs that can interact with lanreotide, such as cyclosporin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lanreotide (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-70 year ;~2. The diagnosis of acute pancreatitis according to the revised Atlanta classification.~3. IAH is defined as IAP ≥ 12 mmHg by the World Society of Abdominal;Compartment Syndrome (WSACS);~4. After 24 hours of conventional treatment(such as gastrointestinal decompression or percutaneous drainage of ascites), the IAP of AP patients with IAH was still ≥ 12 mmHg;~5. The onset time of acute pancreatitis was within 2 weeks;~6. Signed the informed consent.~Exclusion Criteria:~1. Previous history of laparotomy;~2. Mechanical ileus or abdominal hemorrhage were considered clinically;~3. Those who have contraindications to neostigmine: 1) Patients with angina; 2) myocardial infarction; 3) ventricular tachycardia; 4) bradycardia; 5) acute circulatory failure; 6) epilepsy; 7) bronchial asthma; 8) mechanical intestinal obstruction; 9) urinary tract infarction; 10) hyperthyroidism; 11) serious arrhythmia; 12) bladder operation; 13) intestinal fistula;~4. Allergic to neostigmine;~5. Pregnant or lactating patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Neostigmine (Type: EXPERIMENTAL): Intramuscular injection of neostigmine on the basis of conventional conservative treatment
- Conservative treatment (Type: OTHER): Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women greater that 18 undergoing vaginal hysterectomy for any indication, with or without concomitant procedures~Exclusion Criteria:~* women with a significant medical condition, including severe liver disease, congestive heart failure, documented coronary artery disease, impaired renal function determined by an elevated serum creatinine, asthma with steroid use in the past year, and migraines

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No injection (Type: NO_INTERVENTION): Patients did not receive an injection at cervix prior to beginning the procedure
- Injection of vasopressin (Type: EXPERIMENTAL): Patients will be randomized to receive 20cc of dilute vasopressin (20units in 50cc normal saline)injected at cervix at beginning of the hysterectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete